Select Publications

Publications discussed by Dr Pritchard

Levine MN et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16(8):2651-8. Abstract

Pritchard KI et al. A randomized trial comparing CEF to CMF in premenopausal women with nodepositive breast cancer: Update of NCIC CTG MA.5. Breast Cancer Res Treat 2002:Abstract 17.

Therasse P et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21(5):843-50. Abstract

Therasse P et al. Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer (LABC): An EORTC---NCIC---SAKK randomized phase III study comparing FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (filgrastim). Proc ASCO 1998:Abstract.

Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: Rationale for the MA.21 study. Oncology (Huntingt) 2001;15(5 Suppl 7):7-13. Abstract

Induction chemotherapy for locally advanced breast cancer

Ahlgren J et al. Phase II study of epirubicin, cisplatin and capecitabine as neo-adjuvant chemotherapy in women with locally advanced or inflammatory breast cancer. Proc ASCO 2003;Abstract 107.

Alkhatib F et al. Docetaxel and epirubicin as neoadjuvant chemotherapy in patients with locally advanced breast cancer. Proc ASCO 2002:Abstract 2068.

Baltali E et al. Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in localregionally advanced breast cancer: A preliminary report. Tumori 2002;88(6):474-7. Abstract

Braud AC et al. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: Phase II study. Am J Clin Oncol 2002;25(3):303-7. Abstract

Chow LW et al. Neoadjuvant celecoxib and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) for the treatment of locally advanced breast cancer (LABC). Proc ASCO 2003;Abstract 327.

Davidson N et al. Improved outcome following treatment with sequential primary chemotherapy Doxorubicin (A) cyclophosphamide (C)x4 and paclitaxel (P) x4 compared to AC x6 for locally advanced breast cancer (LABC). Proc ASCO 2003;Abstract 353.

de Matteis A et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: A single-center, phase II study. Cancer 2002;94(4):895-901. Abstract

Ezzat A et al. Dose dense neoadjuvant sequential chemotherapy in the management of locally advanced breast cancer: A phase II study. Proc ASCO 2003;Abstract 202.

Ezzat AA et al. High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat 2000;62(3):237-44. Abstract

Fornasiero A et al. Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma. Tumori 2001;87(4):223-8. Abstract

Gajdos C et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80(1):4-11. Abstract

Gogas H et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: A phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002;13(11):1737-42. Abstract

Ikeda T et al. The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer 2002;9(1):8-14. Abstract

Lara F et al. High pathological complete response (PCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Proc ASCO 2000:Abstract 492.

Maldonado D et al. Neoadjuvant chemotherapy with fluorouracil-epirubicin-cyclophosphamide (FEC) and GM-CSF every 14 days in locoregionally advanced breast cancer (LABC): Preliminary report. Proc ASCO 2000:Abstract 486.

Malhotra V et al. Neoadjuvant and adjuvant chemotherapy (CT) with doxorubicin and docetaxel (DD) with surgery and radiation in locally advanced breast cancer. Proc ASCO 2001:Abstract 1771.

Milla-Santos A et al. Anastrozole is an effective neoadjuvant therapy for patients with hormonedependent, locally-advanced breast cancer irrespective of cerbB2. Proc ASCO 2003;Abstract 154.

Morrell L et al. MVAC as neoadjuvant therapy in locally advanced and inflammatory breast cancer: Ten year update. Proc ASCO 2003;Abstract 244.

Ozmen V et al. Inflammatory breast cancer: Results of anthracycline-based neoadjuvant chemotherapy. Breast J 2003;9(2):79-85. Abstract

Paciucci PA et al. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs 2002;13(8):791-5. Abstract

Petruzelka LB et al. Neoadjuvant chemotherapy with vinorelbine and epirubicine in locally advanced breast cancer (LABC): Preliminary report. Proc ASCO 2001:Abstract 1898.

Puglisi F et al. Phase II trial of neoadjuvant chemotherapy with doxorubicin and cyclophosphamide followed by docetaxel in stage II-III breast cancer. Proc ASCO 2002:Abstract 1993.

Shannon C, Smith I. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 2003;45(1):77-90. Abstract

Toi M et al. Celecoxib anti-aromatase neoadjuvant (CAAN) therapy for locally advanced breast cancer: Preliminary results of a prospective randomized trial. Proc ASCO 2003;Abstract 331.

Wolff AC, Davidson NE. Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease. Oncologist 2002;7(3):239-45. Abstract

Home · Search